Male Urethritis in Emergency Medicine Medication

  • Author: Michael C Plewa, MD; Chief Editor: Erik D Schraga, MD   more...
 
Updated: May 11, 2012
 

Medication Summary

In the emergency department, single-dose antibiotic therapy for urethritis is administered to cover both gonococcal urethritis (GCU) and nongonococcal urethritis (NGU), since results of NAAT testing may not be immediately available, and compliance with outpatient treatment and follow-up may be uncertain. Consider presumptive treatment for T vaginalis, or base treatment on evidence of this organism on urine microscopy.

Therapy for GCU

The antimicrobial options in the treatment of GCU include ceftriaxone 125 mg IM single dose or cefixime 400 mg PO single dose. Alternative choices include a single-dose cephalosporin, such as ceftizoxime 500 mg IM or cefoxitin 2 g IM with probenecid 1 g PO, or cefotaxime 500 mg IM, or single-dose spectinomycin 2 g IM (reserved for patients with allergies to cephalosporins and not currently available in the United States). Single-dose azithromycin 2 g PO is also an alternative, but it may cause gastrointestinal distress and has theoretical concern for emerging resistance.

Quinolone resistance is increasing worldwide and is common in Asia, the Pacific, Europe, and the Middle East as well as in some parts of the United States.[16] Quinolone-resistant GCU is also more prevalent in men who have sex with men. Because of increasing resistance, quinolones (eg, ciprofloxacin 500 mg PO single dose, levofloxacin 250 mg PO single dose, or ofloxacin 400 mg PO single dose) are not currently recommended by the Centers for Disease Control and Prevention (CDC) for routine or alternative regimens.[11, 12, 17]

The recommendation was based on analysis of new data from the CDC's Gonococcal Isolate Surveillance Project (GISP). The data from GISP showed the proportion of gonorrhea cases in heterosexual men that were fluoroquinolone-resistant (QRNG) reached 6.7%, an 11-fold increase from 0.6% in 2001. The data were published in the April 13, 2007, issue of the Morbidity and Mortality Weekly Report.[17] This limits treatment of gonorrhea to drugs in the cephalosporin class (eg, ceftriaxone 125 mg IM once as a single dose).

Fluoroquinolones may be an alternative treatment option for disseminated gonococcal infection if antimicrobial susceptibility can be documented. For more information see, the CDC's Antibiotic-Resistant Gonorrhea Web site; CDC Updated Gonococcal Treatment Recommendations (April 2007); or Medscape Medical News on CDC Issues - New Treatment Recommendations for Gonorrhea.

Therapy for NGU

A single dose of azithromycin 1 g orally or doxycycline 100 mg orally twice daily for 7 days has been recommended for treatment of NGU by the CDC.[11, 12] Doxycycline may have a higher clearance rate for Chlamydia than azithromycin[18] ; however, azithromycin is more effective than doxycycline for M genitalium[19, 20, 18] and U urealyticum infections. Single-dose azithromycin may induce resistance in M genitalium[21] but also ensures compliance and may successfully treat cases of NGU in which test results are negative for Chlamydia, Mycoplasma, and Ureaplasma species.[22, 23]

Alternative regimens include 10 days of moxifloxacin 400 mg daily (which may be more effective than azithromycin for M genitalium),[24, 25, 26] 7 days of erythromycin base 500 mg 4 times daily, erythromycin ethylsuccinate 800 mg 4 times daily, ofloxacin 300 mg twice daily, or levofloxacin 500 mg once daily.[11, 12] Minocycline or tetracycline are reasonable alternatives to doxycycline. Ciprofloxacin is ineffective against chlamydial infection. Combinations of probenecid with penicillin, amoxicillin, or ampicillin are no longer used because of resistance.

Therapy for T vaginalis

Consider empiric treatment for T vaginalis (although this organism may be present in as few as 2.5% of urethritis cases),[5] or base treatment on presence of this organism on urine microscopy, with single treatment of metronidazole or tinidazole 2 g orally.

Antibiotic therapy with 2 g metronidazole or tinidazole is also recommended for sexual partners of individuals with documented Trichomonas, even if asymptomatic.

Therapy for recurrent or persistent urethritis

Recurrent symptoms may be related to reexposure (especially if sexual partner not also treated), noncompliance, chronic nonbacterial prostatitis, or infection with T vaginalis, M genitalium, or U urealyticum.

A single dose of metronidazole 2 g orally, or tinidazole 2 g orally, should be used (especially if not given initially) for suspected Trichomonas.

M genitalium can be a common cause of persistent urethritis, especially after doxycycline therapy,[27] but also after azithromycin therapy. Therefore, a single-dose azithromycin 1 g is recommended[19, 28] if the patient did not previously receive azithromycin (or cannot afford quinolones). Moxifloxacin 400 mg daily for 10 days is recommended if the patient previously received azithromycin.[24, 25, 26, 28]

Prolonged (14-28 d) therapy with erythromycin has not been demonstrated to be of value.

Next

Antibiotics

Class Summary

Single-dose therapy to cover GCU and chlamydia includes azithromycin 2 g PO (limited by gastrointestinal intolerance) or azithromycin 1 g PO plus a cephalosporin.

Cefixime (Suprax)

 

Arrests bacterial cell wall synthesis and inhibits bacterial growth by binding to one or more penicillin-binding proteins.

Ceftriaxone (Rocephin)

 

Used because of increasing prevalence of penicillinase-producing N gonorrhoeae. Third-generation cephalosporin with broad-spectrum, gram-negative activity; lower efficacy against gram-positive organisms; higher efficacy against resistant organisms; arrests bacterial growth by binding to one or more penicillin-binding proteins.

Spectinomycin (Trobicin)

 

Structurally different from related aminoglycosides, inhibits protein synthesis in bacterial cells. Site of action is 30S ribosomal subunit. Used as alternative antimicrobial in treatment of urethral, endocervical, or rectal gonococcal infections in patients who cannot take cephalosporins or fluoroquinolones. Same regimen of this medication administered to pregnant women who are allergic to cephalosporins.

Azithromycin (Zithromax)

 

Used to treat mild to moderately severe infections caused by susceptible strains of microorganisms. Indicated for chlamydia and gonorrheal infections of genital tract.

Doxycycline (Dory, Bio-Tab)

 

Used in treatment of rectal syphilis. Inhibits protein synthesis and bacterial growth by binding with 30S and possibly 50S ribosomal subunits of susceptible bacteria.

Tetracycline (Sumycin)

 

Treats susceptible bacterial infections of both gram-positive and gram-negative organisms as well as mycoplasmal, chlamydial, and rickettsial infections. Inhibits bacterial protein synthesis by binding with 30S and possibly 50S ribosomal subunits of susceptible bacteria.

Minocycline (Dynacin, Minocin)

 

Treats infections caused by susceptible gram-negative and gram-positive organisms, in addition to susceptible chlamydial, rickettsial, and mycoplasmal infections.

Erythromycin (E-Mycin, Eryc, Ery-Tab)

 

Indicated for treatment of infections caused by susceptible strains of microorganisms, including Staphylococcus aureus. Inhibits RNA-dependent protein synthesis, possibly by stimulating dissociation of peptidyl tRNA from ribosomes, thus inhibiting bacterial growth. Twice-a-day dosing not recommended when doses greater than 1 g/d are administered.

Metronidazole (Flagyl)

 

Imidazole ring-based antibiotic active against various anaerobic bacteria and protozoa. Usually used in combination with other antimicrobial agents except when used for Clostridium difficile enterocolitis in which monotherapy is appropriate. Active against various anaerobic bacteria and protozoa. Appears to be absorbed into cells, and intermediate-metabolized compounds that are formed bind DNA and inhibit protein synthesis, causing cell death.

Previous
Next

Antibiotic, Quinolone

Class Summary

The quinolone class antibiotics are no longer considered effective against GCU due to increasing resistance. However, these antibiotics are useful for NGU as initial alternative to or when refractory to initial treatment with azithromycin.

Moxifloxacin (Avelox)

 

Inhibits the A subunits of DNA gyrase, resulting in inhibition of bacterial DNA replication and transcription. Useful for refractory NGU secondary to Mycoplasma genitalium infection.

Ofloxacin (Floxin)

 

Treats GU only. Penetrates prostate well and is effective against N gonorrhea and C trachomatis. A derivative of pyridine carboxylic acid with broad-spectrum bactericidal effect. Useful for the treatment of NGU.

Levofloxacin (Levaquin)

 

For pseudomonal infections and infections due to multidrug resistant gram-negative organisms as well as atypical infections such as Chlamydia, Mycoplasma and Ureaplasma species.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Michael C Plewa, MD  Research Coordinator, Consulting Staff, Department of Emergency Medicine, Lucas County Emergency Physicians, Inc, and Mercy Saint Vincent Medical Center

Michael C Plewa, MD, is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, Physicians for Social Responsibility, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

David S Howes, MD  Professor of Medicine and Pediatrics, Emergency Medicine Residency Program Director Emeritus, Head, Phemister Society, University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine

David S Howes, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Richard H Sinert, DO  Professor of Emergency Medicine, Clinical Assistant Professor of Medicine, Research Director, State University of New York College of Medicine; Consulting Staff, Department of Emergency Medicine, Kings County Hospital Center

Richard H Sinert, DO is a member of the following medical societies: American College of Physicians and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

John D Halamka, MD, MS  Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center

John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Chief Editor

Erik D Schraga, MD  Staff Physician, Department of Emergency Medicine, Mills-Peninsula Emergency Medical Associates

Disclosure: Nothing to disclose.

References
  1. Gaydos CA, Maldeis N, Hardick A, Hardick J, Quinn TC. Mycoplasma genitalium Compared to Chlamydia, Gonorrhea, and Trichomonas as an Etiologic Agent of Urethritis in Men Attending STD Clinics. Sex Transm Infect. Apr 20 2009;[Medline].

  2. Iser P, Read TH, Tabrizi S, Bradshaw C, Lee D, Horvarth L, et al. Symptoms of non-gonococcal urethritis in heterosexual men: a case control study. Sex Transm Infect. Apr 2005;81(2):163-5. [Medline].

  3. Moi H, Reinton N, Moghaddam A. Mycoplasma genitalium is associated with symptomatic and asymptomatic non-gonococcal urethritis in men. Sex Transm Infect. Feb 2009;85(1):15-8. [Medline].

  4. Wetmore CM, Manhart LE, Golden MR. Idiopathic urethritis in young men in the United States: prevalence and comparison to infections with known sexually transmitted pathogens. J Adolesc Health. Nov 2009;45(5):463-72. [Medline].

  5. Wetmore CM, Manhart LE, Lowens MS, Golden MR, Whittington WL, Xet-Mull AM, et al. Demographic, behavioral, and clinical characteristics of men with nongonococcal urethritis differ by etiology: a case-comparison study. Sex Transm Dis. Mar 2011;38(3):180-6. [Medline].

  6. Herz D, Weiser A, Collette T, Reda E, Levitt S, Franco I. Dysfunctional elimination syndrome as an etiology of idiopathic urethritis in childhood. J Urol. Jun 2005;173(6):2132-7. [Medline].

  7. Eradi B, Ninan GK. Intravesical steroid instillation--a novel therapeutic intervention for idiopathic urethritis of childhood. Eur J Pediatr Surg. Apr 2009;19(2):105-7. [Medline].

  8. Furuya R, Takahashi S, Furuya S, Saitoh N, Ogura H, Kurimura Y, et al. Is urethritis accompanied by seminal vesiculitis?. Int J Urol. Jul 2009;16(7):628-31. [Medline].

  9. Shahmanesh M, Moi H, Lassau F, Janier M. 2009 European guideline on the management of male non-gonococcal urethritis. Int J STD AIDS. Jul 2009;20(7):458-64. [Medline].

  10. Kirsch TD, Shesser R, Barron M. Disease surveillance in the ED: factors leading to the underreporting of gonorrhea. Am J Emerg Med. Mar 1998;16(2):137-40. [Medline].

  11. [Guideline] CDC. 2006 guidelines for treatment of sexually transmitted diseases. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep. 55(RR-11):1-94. [Full Text].

  12. [Guideline] CDC, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. Aug 4 2006;55(RR-11):1-94. [Medline].

  13. Orellana MA, Gómez-Lus ML, Lora D. Sensitivity of Gram stain in the diagnosis of urethritis in men. Sex Transm Infect. Feb 2 2012;[Medline].

  14. Rietmeijer CA, Mettenbrink CJ. Recalibrating the Gram stain diagnosis of male urethritis in the era of nucleic acid amplification testing. Sex Transm Dis. Jan 2012;39(1):18-20. [Medline].

  15. Hobbs MM, Lapple DM, Lawing LF, Schwebke JR, Cohen MS, Swygard H, et al. Methods for detection of Trichomonas vaginalis in the male partners of infected women: implications for control of trichomoniasis. J Clin Microbiol. Nov 2006;44(11):3994-9. [Medline].

  16. Chen PL, Hsieh YH, Lee HC, et al. Suboptimal therapy and clinical management of gonorrhoea in an area with high-level antimicrobial resistance. Int J STD AIDS. Apr 2009;20(4):225-8. [Medline].

  17. CDC. Update to CDC's Sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR [serial online]. Apr 13 2007;56(14):332-334. Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5614a3.htm?s_cid=mm5614a3_e.

  18. Schwebke JR, Rompalo A, Taylor S, Seña AC, Martin DH, Lopez LM, et al. Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens--a randomized clinical trial. Clin Infect Dis. Jan 15 2011;52(2):163-70. [Medline]. [Full Text].

  19. Mena LA, Mroczkowski TF, Nsuami M, Martin DH. A randomized comparison of azithromycin and doxycycline for the treatment of Mycoplasma genitalium-positive urethritis in men. Clin Infect Dis. Jun 15 2009;48(12):1649-54. [Medline].

  20. Falk L, Fredlund H, Jensen JS. Tetracycline treatment does not eradicate Mycoplasma genitalium. Sex Transm Infect. Aug 2003;79(4):318-9. [Medline].

  21. Jensen JS, Bradshaw CS, Tabrizi SN, Fairley CK, Hamasuna R. Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. Clin Infect Dis. Dec 15 2008;47(12):1546-53. [Medline].

  22. Maeda S, Yasuda M, Ito S, Seike K, Ito S, Deguchi T. Azithromycin treatment for nongonococcal urethritis negative for Chlamydia trachomatis, Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma parvum, and Ureaplasma urealyticum. Int J Urol. Feb 2009;16(2):215-6. [Medline].

  23. Takahashi S, Matsukawa M, Kurimura Y, et al. Clinical efficacy of azithromycin for male nongonococcal urethritis. J Infect Chemother. Dec 2008;14(6):409-12. [Medline].

  24. Bradshaw CS, Chen MY, Fairley CK. Persistence of Mycoplasma genitalium following azithromycin therapy. PLoS One. 2008;3(11):e3618. [Medline].

  25. Bradshaw CS, Jensen JS, Tabrizi SN, Read TR, Garland SM, Hopkins CA, et al. Azithromycin failure in Mycoplasma genitalium urethritis. Emerg Infect Dis. Jul 2006;12(7):1149-52. [Medline].

  26. Jernberg E, Moghaddam A, Moi H. Azithromycin and moxifloxacin for microbiological cure of Mycoplasma genitalium infection: an open study. Int J STD AIDS. Oct 2008;19(10):676-9. [Medline].

  27. Wikstrom A, Jensen JS. Mycoplasma genitalium: a common cause of persistent urethritis among men treated with doxycycline. Sex Transm Infect. Aug 2006;82(4):276-9. [Medline].

  28. Manhart LE, Broad JM, Golden MR. Mycoplasma genitalium: should we treat and how?. Clin Infect Dis. Dec 2011;53 Suppl 3:S129-42. [Medline]. [Full Text].

  29. Hamasuna R, Takahashi S, Uehara S, Matsumoto T. Should urologists care for the pharyngeal infection of Neisseria gonorrhoeae or Chlamydia trachomatis when we treat male urethritis?. J Infect Chemother. Feb 4 2012;[Medline].

  30. Shigehara K, Kawaguchi S, Sasagawa T, Furubayashi K, Shimamura M, Maeda Y, et al. Prevalence of genital Mycoplasma, Ureaplasma, Gardnerella, and human papillomavirus in Japanese men with urethritis, and risk factors for detection of urethral human papillomavirus infection. J Infect Chemother. Aug 2011;17(4):487-92. [Medline].

  31. Lau CY, Qureshi AK. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials. Sex Transm Dis. Sep 2002;29(9):497-502. [Medline].

  32. Lyss SB, Kamb ML, Peterman TA, et al. Chlamydia trachomatis among patients infected with and treated for Neisseria gonorrhoeae in sexually transmitted disease clinics in the United States. Ann Intern Med. Aug 5 2003;139(3):178-85. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.